Shire's Daytrana Patch Recall Is 8th So Far: Time to Pull the Plug? | BNET Pharma Blog | BNET
Links shared publicly online about this topic.
- 1,548total visits
Shire's Daytrana Patch Recall Is 8th So Far: Time to Pull the Plug? | BNET Pharma Blog | BNET
View full resource at industry.bnet.com
Tags: ADHD, Pharma, Shire, Safety
Most Recently Shared on December 7, 2009 at 4:49 pm By:
Shire's Daytrana Patch Recall Is 8th So Far: Time to Pull the Plug?: Shire (SHPGY) has voluntarily recalled the Day... http://bit.ly/5d1A9H
preview
emailactivity.ecn5.com — “preview” View full resource at emailactivity.ecn5.com
Most Recently Shared on April 4, 2012 at 12:30 pm By:
PharmaLive Pharma and Health News
#Shire Reaffirms Support of Patients Requiring Midodrine HCl http://t.co/4u92Z2MX #TherapeuticsDaily
ADHD Scholarship Deadline is Friday, March 30, 2012 | Edge ADHD Coaching
edgefoundation.org — “Stop procrastinating and apply for the Edge/Shire ADHD scholarship TODAY!” View full resource at edgefoundation.org
Most Recently Shared on March 26, 2012 at 9:19 pm By:
Laura Rolands, Attention and Productivity Coach Health Professional
Blog Post = ADHD Scholarship Deadline is Friday, March 30, 2012: Students who have been putting o... http://t.co/rW6E8YQ1 = via @EdgeFdn
Shire signs CNS disorders deal with Heptares | InPharm
inpharm.com — “InPharm.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, jobs, events, and service company listings.” View full resource at inpharm.com
Most Recently Shared on March 23, 2012 at 3:32 pm By:
Pharmafocus Pharma and Health News
Shire signs CNS disorders deal with Heptares - http://t.co/9SvsWoVW
Shire chairman took home £8.5m | Business | The Guardian
guardian.co.uk — “Matthew Emmens, chairman of Shire, took home £8.5m in 2011 after a series of share-related deals paid out” View full resource at guardian.co.uk
Most Recently Shared on March 22, 2012 at 10:46 pm By:
Shire chairman took home £8.5m http://t.co/EA8ACxDX via @guardian
Heptares - News Detail
heptares.com — “Heptares Therapeutics” View full resource at heptares.com
Most Recently Shared on March 20, 2012 at 12:23 pm By:
Lisa Jarvis Science Enthusiast
Shire licenses Heptares preclin candidate for CNS disorders, targets GPCR Adenosine A24: http://t.co/zcoIH7VY
Heptares exercises exclusive option to license new A2A antagonist for CNS disorders
news-medical.net — “Heptares Therapeutics, the leading GPCR drug discovery company, announces that an operating company of Shire PLC, the global specialty biopharmaceutical company, has exercised its exclusive option to license a novel adenosine A2A antagonist discovered by Heptares that is currently in preclinical development.” View full resource at news-medical.net
Most Recently Shared on March 20, 2012 at 8:18 am By:
Alzheimers News: Heptares exercises exclusive option to license new A2A antagonist for CNS disorders: Heptares T... http://t.co/N8EWFN8G
Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders - MarketWatch
marketwatch.com — “Heptares Grants Shire an Exclusive Worldwide Licence to Develop and Commercialise Novel Drug Candidate for CNS Disorders - MarketWatch” View full resource at marketwatch.com
Most Recently Shared on March 20, 2012 at 7:48 am By:
John Carroll Health Communicator
Heptares (Fierce 15 co., GPCR discovery platform in UK) forges $190M licensing pact with Shire on CNS drug program. http://t.co/rwlDYB8l
Medical News:Shire Quits on Fabry Drug - in Genetics, Genetics from MedPage Today
medpagetoday.com — “Medical News:Shire Quits on Fabry Drug - in Genetics, Genetics from MedPage Today” View full resource at medpagetoday.com
Most Recently Shared on March 15, 2012 at 10:59 pm By:
Urology & Nephrology OW Health
Shire Quits on Fabry Drug: (MedPage Today) -- Shire PLC has withdrawn its U.S. application to market an enzyme r... http://t.co/T2h3QjlU
Medical News:Shire Quits on Fabry Drug - in Genetics, Genetics from MedPage Today
medpagetoday.com — “Medical News:Shire Quits on Fabry Drug - in Genetics, Genetics from MedPage Today” View full resource at medpagetoday.com
Most Recently Shared on March 15, 2012 at 10:09 pm By:
Shire Quits on Fabry Drug http://t.co/ar89XArM
Shire Quits on Fabry Drug - QualityPoint Technologies
qualitypointtech.net — “(MedPage Today) -- Shire PLC has withdrawn its U.S. application to market an enzyme replacement therapy for Fabry disease, citing an expected FDA demand for controlled clinical trials.” View full resource at qualitypointtech.net
Most Recently Shared on March 15, 2012 at 10:00 pm By:
Shire Quits on Fabry Drug: (MedPage Today) -- Shire PLC has withdrawn its U.S. application to market an enzyme rep... http://t.co/Yln0Mznt
Medical News:Shire Quits on Fabry Drug - in Genetics, Genetics from MedPage Today
medpagetoday.com — “Medical News:Shire Quits on Fabry Drug - in Genetics, Genetics from MedPage Today” View full resource at medpagetoday.com
Most Recently Shared on March 15, 2012 at 9:49 pm By:
Patricia Grace Eldercare Expert
Shire Quits on Fabry Drug: (MedPage Today) -- Shire PLC has withdrawn its U.S. application to market an enzyme r... http://t.co/GmpxuBBl
Shire exits Fabry's market, citing costs as FDA weighs more research - Medical Marketing and Media
mmm-online.com — “Shire has pulled its drug, Replagal, from FDA review. The company was set to go before the agency next month, but preliminary talks indicated the FDA was going to require more testing.” View full resource at mmm-online.com
Most Recently Shared on March 15, 2012 at 7:44 pm By:
Shire exits Fabry's market, citing costs as FDA weighs more research: Shire has pulled its drug, Repla... http://t.co/Dvk23gmc from MM&M
Shire Shells Out $100M to Buy Ferrokin Biosciences | Xconomy
xconomy.com — “Shire, the Dublin-based pharmaceutical company with operations in the Boston area, is paying $100 million upfront for a little San Francisco company seeking to” View full resource at xconomy.com
Most Recently Shared on March 15, 2012 at 1:53 pm By:
Luke Timmerman Health Communicator
Shire Shells Out $100M to Buy Ferrokin Biosciences | Xconomy http://t.co/IvSpYKiK
Shire Ends Fabry Drug Bid, Giving Sanofi A Boost - Forbes
forbes.com — “In a surprise move, Shire Pharmaceuticals has ended its bid for FDA approval for its Replagal biologic for treating Fabry disease, a rare, but life-threatening genetic disorder. The move comes less than two months after the FDA approved a manufacturing plant operated by Genzyme, which experienced shortages of its own medication for the past two years and is now trying to restoring regular supplies.” View full resource at forbes.com
Most Recently Shared on March 15, 2012 at 1:09 pm By:
Drugs and Devices OW OW Health
Shire Ends Fabry Drug Bid, Giving Sanofi A Boost: In a surprise move, Shire Pharmaceuticals has ended its ... http://t.co/9MC2NTKo #drug
Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment - Drugs.com MedNews
drugs.com — “Shire plc (LSE SHP, NASDAQ SHPGY), the global specialty biopharmaceutical company, announces that it has signed an agreement to acquire FerroKin BioSciences, In” View full resource at drugs.com
Most Recently Shared on March 15, 2012 at 12:05 pm By:
Drugs and Devices OW OW Health
Shire to Acquire FerroKin BioSciences, Inc., and its Phase 2 Iron Chelator Treatment: DUBLIN, March 15, 20... http://t.co/g9ekBM4J #drug
Advertisement
